Nektar Therapeutics buy Oppenheimer Holdings Inc.
Start price
14.03.25
/
50%
€0.82
Target price
14.03.26
€5.53
Performance (%)
-29.01%
End price
15.03.26
-
Summary
This prediction is currently being closed. The prediction for Nektar Therapeutics disappoints with a performance of -29.01%. Oppenheimer_Holdings has a follow-up prediction for Nektar Therapeutics where he still thinks Nektar Therapeutics is a Buy. Oppenheimer_Holdings has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | 2.554% | 0.562% | 14.142% |
| iShares Nasdaq 100 | 2.742% | -0.599% | 30.370% |
| iShares Nikkei 225® | 6.584% | 4.336% | 49.372% |
| iShares S&P 500 | 1.930% | -0.507% | 24.257% |
Comments by Oppenheimer_Holdings for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $6.00 price target on the stock.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von Oppenheimer_Holdings gewählte maximale Laufzeit wurde überschritten